|
1. A method of enhancing delivery of a cannabinoid to the central nervous system; comprising orally administering to a patient in need thereof, an effective amount of a pharmaceutical composition comprising a cannabinoid-infused powder, wherein the cannabinoid-infused powder comprises a cannabinoid active pharmaceutical ingredient (API) in an amount of (a) 4%-6% CBD and (b) 0.2% to 0.7% CBG and/or 0.2% to 0.7% CBN, by weight of the cannabinoid-infused powder; an edible oil consisting of 5-10% sunflower seed oil, by weight of the cannabinoid-infused powder; and an edible carrier selected from silicon dioxide, starch, dried plant material and mixtures thereof, wherein the edible carrier comprises 80%-90% by weight of the cannabinoid infused powder, and wherein the cannabinoid-infused powder does not contain any additional oil.
|